Darmiyan

As Darmiyan Chief of Communications and Public Relations and manning Darmiyan's Bethesda/Washington office I am delighted to be raising awareness of this originally Nobel laureate approved and now third-party validated technology. In July 2020 I also became Head of US Strategic Partnerships and joined the global team full-time in 2021.I work closely with the Darmiyan leadership to implement our strategic plans and objectives. With a focus on the US market I develop relationships with… As Darmiyan Chief of Communications and Public Relations and manning Darmiyan's Bethesda/Washington office I am delighted to be raising awareness of this originally Nobel laureate approved and now third-party validated technology. In July 2020 I also became Head of US Strategic Partnerships and joined the global team full-time in 2021.I work closely with the Darmiyan leadership to implement our strategic plans and objectives. With a focus on the US market I develop relationships with various stakeholders such as geriatricians, family physicians, wellness centers and MRI imaging clinics. We are on a mission to become the universally accepted and available standard of care for the early detection and monitoring of Alzheimer's dementia. Darmiyan's novel noninvasive brain diagnostic can detect dementia related to Alzheimer’s disease before symptoms, exactly when treatments are feasible and mild cognitive impairment could be slowed by simple lifestyle changes.Darmiyan means "in between;" we believe many answers may soon be read between the MRI lines. With additional non-invasive modeling in this microscopic space, we will bring clarity to the mysterious development of this disease, and prepare the field for new therapies and treatments.With our diagnostic tools providers will be able to examine the brain while living. They will not have to wait for the brain to die to have clarity about Alzheimer's.Technically speaking we offer a novel medical image processing technology for objective accurate and non-invasive early diagnosis, monitoring and prognosis of Alzheimer's disease in clinics and clinical trials. Its highly automated cloud-based platform may be readily accessed by radiologists and other clinicians. Darmiyan is backed by Eisai, IT-Farm, YC and other amazing investors. With additional funding it could be used to monitor other brain degenerative diseases.